Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 602

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study

Open access
Mohile, Supriya G, Mohamed, Mostafa R, Xu, Huiwen, Culakova, Eva, Loh, Kah Poh, Magnuson, Allison, Flannery, Marie A, Obrecht, Spencer, Gilmore, Nikesha, Ramsdale, Erika, Dunne, Richard F, Wildes, Tanya, Plumb, Sandy, Patil, Amita, Wells, Megan, Lowenstein, Lisa, Janelsins, Michelle, Mustian, Karen, Hopkins, Judith O, Berenberg, Jeffrey, Anthony, Navin, Dale, William·2021·The Lancet

Abstract

Summary Background: Older adults with advanced cancer are at high risk for treatment toxicity. Geriatric assessment (GA) evaluates aging-related domains and guides management. We examined whether a GA intervention can reduce serious toxicity in older patients with advanced cancer receiving high risk treatment (e.g., chemotherapy). Methods: In this cluster randomized trial, we enrolled patients aged ≥ 70 with incurable solid tumors or lymphoma and at least one impaired GA domain starting a new treatment regimen. Community oncology practice clusters across the United States (n=40) were randomized to intervention (oncologists received a tailored GA summary and management recommendations) or usual care. The primary outcome was the proportion of patients who experienced any grade 3–5 toxicity (NCI’s Common Terminology Criteria for Adverse Events V4.0) over 3 months. Practice staff prospectively captured toxicities; blinded oncology clinicians reviewed medical records to verify. Secondary outcomes included overall survival (OS), treatment intensity, and GA outcomes. Trial Registration: NCT02054741 Findings: From 2014–19, we enrolled 718 patients. Age (mean 77·2 years), sex (43·3% female), number of impaired GA domains (median 4·5/8), and treatment (chemotherapy 88·2%) did not differ by arm. More patients in intervention were Black versus other race (11·5% vs 3·3%, p<0·01) and had prior chemotherapy (30·8% vs 22·7%, p=0·02). A lower proportion of patients in intervention experienced grade 3–5 toxicity (177/349; 50·7%) than in usual care (263/369; 71·2%); relative risk (RR) was 0·74 (95% CI: 0·64–0·86; p<0·001). While more patients in intervention received reduced intensity treatment at cycle 1, OS was not different by arm at 6 months. Patients in intervention experienced fewer falls over 3 months (11·7% vs 20·7%; RR 0·58, p<0·01) and had more medications discontinued (mean adjusted difference 0·14, p=0·02). Interpretation: A GA intervention for older patients with advanced cancer reduced serious toxicity from cancer treatment without compromising OS. Funding: National Cancer Institute

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)01789-x

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 602

Metadata

Authors
Mohile, S. G., Mohamed, M. R., Xu, H., Culakova, E., Loh, K. P., Magnuson, A., Flannery, M. A., Obrecht, S., Gilmore, N., Ramsdale, E., Dunne, R. F., Wildes, T., Plumb, S., Patil, A., Wells, M., Lowenstein, L., Janelsins, M., Mustian, K., Hopkins, J. O., Berenberg, J., Anthony, N., & Dale, W.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-11
Volume
398
Issue
10314
Pages
1894-1904
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3209480926
Cited by
602
References
31
FWCI
45.17
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. https://app.cochat.ai/papers/10.1016/s0140-6736(21)01789-x
The paper
Mohile, S. G., Mohamed, M. R., Xu, H., Culakova, E., Loh, K. P., Magnuson, A., Flannery, M. A., Obrecht, S., Gilmore, N., Ramsdale, E., Dunne, R. F., Wildes, T., Plumb, S., Patil, A., Wells, M., Lowenstein, L., Janelsins, M., Mustian, K., Hopkins, J. O., . . . Dale, W. (2021). Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study. The Lancet. https://doi.org/10.1016/s0140-6736(21)01789-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.